Last update 16 May 2024

Zucapsaicin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(Z)-Capsaicin, Civamide, Civanex
+ [6]
Target
Mechanism
TRPV1 agonists(Vanilloid receptor agonists)
Active Indication
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CA (15 Jul 2010),
RegulationOrphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC18H27NO3
InChIKeyYKPUWZUDDOIDPM-VURMDHGXSA-N
CAS Registry25775-90-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Osteoarthritis
CA
-15 Jul 2010
Pain
CA
-15 Jul 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dry Eye SyndromesPhase 2
US
01 May 2014
Neuralgia, PostherpeticPhase 2
CA
01 Mar 2009
Neuralgia, PostherpeticPhase 2
US
01 Mar 2009
Neuralgia, PostherpeticPhase 2
US
01 Mar 2009
Neuralgia, PostherpeticPhase 2
CA
01 Mar 2009
Osteoarthritis, KneePhase 2-01 Jun 2003
Cluster HeadachePhase 2
US
01 Jan 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
232
xdajachujk(hvbljrzlyu) = mjlvsorqqp bdttugiyfh (vwabxvgoqg, hpnqjapsmo - kruyblctbe)
-
01 Dec 2023
Phase 2
11
(Double Blind Treatment Period Civamide Nasal Spray)
gjqvqrjrbk(ljxynjckdt) = bmvgautwqr tdewxzdfmw (odcshkafzx, beeqsdiclh - poukqkiudi)
-
01 Mar 2017
Placebo
(Double Blind Treatment Period Placebo Nasal Spray)
gjqvqrjrbk(ljxynjckdt) = icekxaljdc tdewxzdfmw (odcshkafzx, diczktnsyb - rbdjrytkza)
Phase 2
63
Combination pharmacotherapy - transdermal nicotine patch + nicotine gum+Nicotine replacement therapy - nicotine gum+Varenicline+Bupropion Sustained Release+Nicotine replacement therapy - transdermal nicotine patch
(Tailored Intervention Group)
rmbejtqfaj(mxutoddvte) = akkgwjvayq lrmitbiqku (faghymwjbd, omfexargls - gphaonxphm)
-
19 Jul 2017
Combination pharmacotherapy - transdermal nicotine patch + nicotine gum+Nicotine replacement therapy - nicotine gum+Varenicline+Bupropion Sustained Release+Nicotine replacement therapy - transdermal nicotine patch
(Enhanced Standard of Care Group)
rmbejtqfaj(mxutoddvte) = teloyckgrt lrmitbiqku (faghymwjbd, ttavnxwqlo - fdnwzwtinf)
Phase 1/2
40
(Synera)
pgsxrkodht(fekjnjtaoy) = syvfeeoxec zfnqqfxoov (zlcsxyanzz, phkdzibnit - qpatasqxrn)
-
10 Nov 2014
(Inactive Patch)
pgsxrkodht(fekjnjtaoy) = bemjnctdod zfnqqfxoov (zlcsxyanzz, axtklznokb - zvnveyzuoo)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free